Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
May 31, 2019
Adaptive Biotechnologies appoints Kevin Conroy and Michelle Griffin to board of directors
Adaptive Biotechnologies today announced Kevin Conroy, chairman and CEO
of Exact Sciences Corporation, and Michelle Griffin, director at Acer
Therapeutics, Inc. and HTG Molecular Diagnostics, Inc., have been
elected to the board of directors. Board member Arnold J. Levine, PhD,
has transitioned to Adaptive’s scientific advisory board.
May 30, 2019
Schrödinger to Present at the Jefferies 2019 Global Healthcare Conference
Schrödinger
today announced that Ramy Farid, Ph.D., chief executive officer, will
present at the Jefferies 2019 Global Healthcare Conference on Thursday,
June 6, 2019 at 11:00 a.m. ET in New York, NY.
May 29, 2019
Studies support dinutuximab beta in treating neuroblastoma – EUSA Pharma
EUSA Pharma’s studies of Qarziba in treatment of high-risk neuroblastoma support the use of dinutuximab beta as standard-of-care immunotherapy for high-risk neuroblastoma patients.
May 29, 2019
FDA grants supplemental nda for Allergan, Gedeon Richter’s Vraylar
Allergan and Gedeon Richter got the U.S. Food and Drug Administration approval for a supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for expanded use to treat depressive episodes associated with bipolar I disorder (bipolar depression) in adults.
May 29, 2019
Ansun Biopharma opens door for patients to test its medication for certain parainfluenza virus infection
Ansun Biopharma has welcomed the first patient to its Phase 3 clinical trial to test DAS181 a recombinant sialidase protein that can cleave sialic acid, the virus receptors located on the surface of epithelial cells lining the human respiratory track.
May 29, 2019
Patch-Safe from Schreiner MediPharm for storage of used transdermal patches
Schreiner MediPharm developed the Patch-Safe specialty label for PS Marketing & Outsourcing GmbH, to be used for safe disposal of patches containing active ingredients.
May 29, 2019
Teva to present new fremanezumab FOCUS Clinical Study Data for the first time at the 13th European Headache Federation Congress
Teva presents 17 posters and three oral presentations at EHF 2019 highlighting long-term and FOCUS Phase IIIb study data The…
May 28, 2019
Transgene included last patient in Phase 2 trial testing TG4010 in combination with Opdivo
Transgene confirms that the study’s primary
endpoint (objective response rate – ORR) on a minimum of 35 evaluable
patients will be reported in Q4 2019.
May 28, 2019
Pfizer’s Phase 3 Trial of LYRICA in primary generalized tonic-clonic seizures misses target
The LYRICA Pediatric Epilepsy Program is composed of six studies in
patients with epilepsy evaluating LYRICA as adjunctive therapy, five of
which have been completed.